MAPK1/3 (Phospho-Tyr205/222) Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-MAPK1/3 (Phospho-Tyr205/222) antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityMAPK1/3 (Phospho-Tyr205/222)
Clonepolyclonal
Host Speciesn/a
Reactive Specieshuman, mouse, rat
Isotypen/a
Formatepitope affinity purified
Size0.1 mg
Concentrationn/a
ApplicationsWestern Blot (WB), ELISA (EIA)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionSpecificity: MAPK1/3 (Phospho-Tyr205/222) antibody detects endogenous levels of MAPK1 only when phosphorylated at tyrosine 204.
ImmunogenImmunogen: The antiserum was produced against synthesized phosphopeptide derived from human MAPK1 around the phosphorylation site of tyrosine 204.
Other Names[ERK; ERK-2; ERK2; ERT1; Extracellular signal-regulated kinase 2; extracellular signal-regulated kinase-2; MAP kinase 1; MAP kinase 2; MAP kinase isoform p42; MAPK 1; MAPK 2; MAPK1; MAPK2; Mitogen-activated protein kinase 1; Mitogen-activated protein kinase 2; MK01; p38; p40; p41; p41mapk; p42-MAPK; P42MAPK; PRKM1; PRKM2; protein tyrosine kinase ERK2], [MAPK1; MAPK1; ERK; p38; p40; p41; ERK2; ERT1; ERK-2; MAPK2; PRKM1; PRKM2; P42MAPK; p41mapk; p42-MAPK; ERK2; PRKM1; PRKM2; MAP kinase 1; MAPK 1; ERK-2; p42-MAPK; MAP kinase 2; MAPK 2]
Gene, Accession #[MAPK1/3], Gene ID: 5594, NCBI: NP_002736.3, UniProt: P28482
Catalog #MBS858002
Price$280
Order / More InfoMAPK1/3 (Phospho-Tyr205/222) Antibody from MYBIOSOURCE INC.
Product Specific ReferencesOwaki H., Biochem. Biophys. Res. Commun. 182:1416-1422(1992). Dunham I., Nature 402:489-495(1999). Dunham I., Nature 402:489-495(1999).
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.